Related references
Note: Only part of the references are listed.nITRO: A phase 2 study of perioperative liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) in patients with resectable pancreatic ductal adenocarcinoma (rPDAC).
Davide Melisi et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3trial
Zev A. Wainberg et al.
LANCET (2023)
Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer
Gabriella Baraks et al.
CANCER RESEARCH (2022)
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
J. H. Strickler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: The SEQUENCE trial.
Alfredo Carrato et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer
Kai Duan et al.
SCIENTIFIC REPORTS (2021)
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing
Smita S. Joshi et al.
CLINICAL CANCER RESEARCH (2020)
Metastatic Pancreatic Cancer: ASCO Guideline Update
Davendra P. S. Sohal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The global burden of pancreatic cancer
Giuseppe Lippi et al.
ARCHIVES OF MEDICAL SCIENCE (2020)
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2
Teresa Macarulla et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer
Vaibhav Sahai et al.
JOURNAL OF PANCREATIC CANCER (2019)
Sequential treatment with Nab-paclitaxel plus Gemcitabine and Folfirinox in metastatic pancreatic adenocarcinoma: GABRINOX phase II results.
Eric Assenat et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in 1st line metastatic pancreatic cancer (MPC).
Vincent J. Picozzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study).
Elisa Giommoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
Kyaw L. Aung et al.
CLINICAL CANCER RESEARCH (2018)
Initial gemcitabine/nab-paclitaxel (GA) followed by sequential (S) mFOLFIRINOX or alternating (A) mFOLFIRI in metastatic pancreatic cancer (mPC): The SEENA-1 study.
Vincent J. Picozzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
FOLFOX plus Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer A Brown University Oncology Research Group Phase I Study
Howard Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Global Trends in Pancreatic Cancer Mortality From 1980 Through 2013 and Predictions for 2017
Aimee L. Lucas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Gabrinox: A phase I-II of nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Eric Assenat et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Modelling prognostic factors in advanced pancreatic cancer
D. D. Stocken et al.
BRITISH JOURNAL OF CANCER (2008)
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis
Robert L. Fine et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
